HIGHLIGHTS
- who: Linkai Jing from the (UNIVERSITY) have published the paper: Diffuse midline glioma treated with epigenetic agent-based immunotherapy, in the Journal: (JOURNAL) of 12/08/2022
- what: The authors provide the first study applying EZH2i as one of epigenetic agents in treating DMG patients.
SUMMARY
Received blood-brain barrier and is a promising agent in treating DMG (Supplementary Table 6). Compassionate use of panobinostat was well-tolerated in four DMG patients, one of which was spinal cord DMG with LM and the OS was 6 months. Similarly, the authors observed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.